Kalorama identifies four trends to watch in the autoimmune immunoassay market


[ad_1]

Currently, a considerable number of diagnostic tests are available or in development for the detection of autoimmune diseases. Due to this potentially large and growing market, vast opportunities exist for discovery and advancement in this field.

The autoimmune immunoassay market will total approximately $ 971.7 million in 2021 and is expected to exceed $ 1 billion by 2026, according to Autoimmune Immunoassay Brief, a recent report by leading medical market researcher Kalorama Information.

The autoimmune immunoassay market, including laboratory autoimmune immunoassays and autoimmune immunoassays based on POCs, represents only a small portion of the total market for IVD immunoassay diagnostic tests, but the prevalence of autoimmune diseases is increasing and the sensitivity of testing continues to improve. In the report, Kalorama Information’s estimates include revenue from reagents and instruments for autoimmune immunoassay testing. It does not understand the services.

Competition in this market is expected to increase significantly. However, in the emerging markets for autoimmune IVD diagnostic testing, there is a golden opportunity to capitalize on new testing innovations without significant competition. Among the companies already operating successfully in the segment, Thermo Fisher and INOVA stand out due to their robust autoimmune immunoassay offerings and impressive pipelines.

“Currently, a considerable number of diagnostic tests are available or in development for the detection of autoimmune diseases. Because of this potentially large and growing market, vast opportunities exist for discovery and advancement in this area, ”says Bruce Carlson, editor of Kalorama Information.

Regarding present and future growth opportunities, Kalorama Information has identified several important trends. These include, but are not limited to:

  • Trend 1: There are vast opportunities for autoimmune diagnostic test product manufacturers in the autoimmune field

Since most autoimmune diseases are of unknown etiology, the potential discovery of many other autoimmune diseases will likely lead to increased opportunities in the discovery, manufacture and commercialization of diagnostic test products for self-IVD. immune.

  • Trend 2: Women are disproportionately affected by autoimmune diseases

Because the population is aging and there will be more aging women, they will be affected more often than men with autoimmune diseases. This will likely create a large demographic group that will benefit from new and sophisticated autoimmune diagnostic tests.

  • Trend 3: Test sophistication leads to efficient, more automated tests

Diagnostic companies continue to gradually improve their fully automated platforms. In addition, many companies are working on the development of new innovative platforms. The demand for health and diagnostic tests in all major markets is driven by aging populations and the increasing incidence of autoimmune diseases. In view of the demand for these tests, they have been reformulated for automated analyzers where the cost per test is traditionally lower.

  • Trend 4: Testing should be cost effective but accurate to identify autoimmune diseases

The commercialization of new and sophisticated IVD products and technologies presents itself as a double-edged sword: some of these new devices and technologies are expected to come at a high price and the payment infrastructure in most countries has not evolved to cover good. many of the new approaches to patient management. As a result, as is often the case, technology is far ahead of healthcare regulation and reimbursement plans. The onus is therefore on the manufacturers to prove that their new intervention is not only effective, but also provides a cost-effective treatment alternative.

For more information, purchase Allergy Immunoassay Brief, available at https://kaloramainformation.com/product/autoimmune-immunoassay-brief/

About Kalorama Information:

Kalorama Information, part of the Science and Medicine Group, is the leading publisher of market research in the fields of healthcare, including in vitro diagnostics (IVD), biotechnology, medical devices and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging and clinical diagnostic companies by helping them create strategies and products to win markets and deliver platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports per year. The firm offers a Knowledge Center, which provides access to all published reports.

Share the article on social media or by email:

[ad_2]

Comments are closed.